[Fusion genes and prostate cancer. From discovery to prognosis and therapeutic perspectives].
The identification of fusion genes provides new insights into the initial mechanisms of molecular events implicated in the prostate cancer tumorigenesis. The presence of TEMPRSS2-ETS fusion in up to half of all human prostate cancer makes it perhaps the most common genetic rearrangement in human epithelial tumors. Some data suggest that TMPRSS2-ERG fusion prostate cancers have a more aggressive phenotype, which may affect cancer progression and outcome in localized tumors treated with prostatectomy. This discovery should pave the way towards future targeted therapies.
Beuzeboc
P
P
Département d'oncologie médicale, Institut Curie, 26, rue d'Ulm, 75005 Paris, France. philippe.beuzeboc@curie.net
Soulié
M
M
Richaud
P
P
Salomon
L
L
Staerman
F
F
Peyromaure
M
M
Mongiat-Artus
P
P
Cornud
F
F
Paparel
P
P
Davin
J-L
JL
Molinié
V
V
D050939:Gene Fusion; D006801:Humans; D008297:Male; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000235:genetics* / Q000628:therapy